Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes ...
(WorldNews Denmark)

Valby, Denmark and Tokyo, Japan, 14 February 2019 H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce today that data from two global Phase III clinical trials evaluating the safety and efficacy of brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder did not meet the primary endpoint. The duration of the randomized phase of each trial was 3 weeks. ......